FDA Clears Investigational NDA for IASO208

Ms. Jinhua Zhang, Founder, Chairwoman, and CEO of IASO Bio, said: “The FDA’s clearance of the IND application for IASO208 represents an important milestone for InTelliCAR™, IASO Bio’s proprietary in vivo CAR-T platform, and marks the entry of China-originated cell therapy technologies into the global race in the in vivo CAR-T field. Leveraging the proprietary InTelliCAR™ platform, IASO Bio has established a pipeline of multiple in vivo CAR-T product candidates spanning hematologic malignancies, autoimmune diseases, and solid tumors, with several of these products already in the IND-enabling stage. The FDA’s clearance of IASO208 based on early IIT data from China reflects the regulator’s recognition of the high quality of China’s IIT clinical data, and lays a solid foundation for the international development of the platform’s pipeline. Going forward, we will continue to advance the clinical development of the InTelliCAR™ platform pipeline to accelerate global patient access to China-originated cell therapies.”

Share:

More News

Taiho Oncology, Inc. completed a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for zipalertinib in combination with platinum-based chemotherapy for the treatment of patients with previously untreated, locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20

“This collaboration reflects our conviction that atebimetinib has the potential to become an essential backbone therapy in a broad range of combinations across MAPK-driven cancers,” said Ben Zeskind, Immuneering CEO and co-founder. “Atebimetinib’s unique tolerability profile and broad activity make it well suited to combine with a wide range of

“These final updated results provide continued evidence of the potential for γδ T cell therapies to drive activity and improve outcomes for patients,” said William Ho, CEO and co-founder of IN8bio. “The clinical outcomes and observed activity are supported by our correlative analysis, including histopathology, demonstrating the expansion and persistence

“Patients with RAS-mutated mCRC have no first-line therapies specifically approved for their disease, and Fast Track designation reflects the potential of onvansertib to address this serious unmet need,” said Mani Mohindru, PhD, President and Chief Executive Officer of Cardiff Oncology. “Our randomized Phase 2 data give us confidence that onvansertib